论文部分内容阅读
膀胱灌注BCG已被广泛证实是一种有效的膀胱内化疗药物;标准的120 mg BCG具有相对高的毒性反应,大约5%的患者存在中等到重度的副反应,高于丝裂霉素等其他药物。本研究拟通过不同剂量BCG的临床研究,判定减低BCG剂量是否可以减少毒性反应同时不影响其治疗效果。从2002年7月至2005
Intravesical BCG has been widely proven to be an effective intravesical chemotherapeutic drug; the standard 120 mg BCG has a relatively high toxicity response, with about 5% of patients presenting with moderate to severe side effects, higher than mitomycin and others drug. This study intended to pass different doses of BCG clinical studies to determine whether to reduce the dose of BCG can reduce the toxic reaction does not affect its therapeutic effect. From July 2002 to 2005